- Home
- IPHA vs BEEP Comparison
IPHA vs BEEP Comparison
Compare IPHA & BEEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- BEEP
- Stock Information
- Founded
- IPHA 1999
- BEEP 2015
- Country
- IPHA France
- BEEP United States
- Employees
- IPHA N/A
- BEEP N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- BEEP Blank Checks
- Sector
- IPHA Health Care
- BEEP Finance
- Exchange
- IPHA Nasdaq
- BEEP Nasdaq
- Market Cap
- IPHA 160.1M
- BEEP 150.7M
- IPO Year
- IPHA 2019
- BEEP N/A
- Fundamental
- Price
- IPHA $1.82
- BEEP $2.99
- Analyst Decision
- IPHA Strong Buy
- BEEP Strong Buy
- Analyst Count
- IPHA 3
- BEEP 2
- Target Price
- IPHA $5.00
- BEEP $6.75
- AVG Volume (30 Days)
- IPHA 572.8K
- BEEP 57.9K
- Earning Date
- IPHA 09-17-2025
- BEEP 11-10-2025
- Dividend Yield
- IPHA N/A
- BEEP N/A
- EPS Growth
- IPHA N/A
- BEEP N/A
- EPS
- IPHA N/A
- BEEP N/A
- Revenue
- IPHA $14,839,695.00
- BEEP $35,470,000.00
- Revenue This Year
- IPHA $22.29
- BEEP $1.29
- Revenue Next Year
- IPHA $43.84
- BEEP $5.56
- P/E Ratio
- IPHA N/A
- BEEP N/A
- Revenue Growth
- IPHA N/A
- BEEP N/A
- 52 Week Low
- IPHA $1.41
- BEEP $2.85
- 52 Week High
- IPHA $3.51
- BEEP $4.86
- Technical
- Relative Strength Index (RSI)
- IPHA 42.84
- BEEP 35.69
- Support Level
- IPHA $1.73
- BEEP $2.89
- Resistance Level
- IPHA $1.86
- BEEP $3.38
- Average True Range (ATR)
- IPHA 0.12
- BEEP 0.20
- MACD
- IPHA -0.02
- BEEP -0.05
- Stochastic Oscillator
- IPHA 11.51
- BEEP 14.93
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About BEEP Mobile Infrastructure Corporation
Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States. The company owns forty three parking facilities in twenty one separate markets throughout the United States, with a total of approximately fifteen thousand seven hundred parking spaces. It operates in a single reportable segment: parking. The company derives majority of revenue from Percentage rental income.